Ireland - English - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/250mcg microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/500mcg microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon pharmaceuticals (ireland) limited - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/500 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - salmeterol xinafoate; fluticasone propionate - powder for inhalation - 50/500 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - fluticasone propionate 0.05mg (additional 5% overage); salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol - aerosol inhaler, metered dose - 0.05mg/0.025mg per dose - active: fluticasone propionate 0.05mg (additional 5% overage) salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol excipient: ethanol lecithin norflurane - reversible obstructive airways disease (road): indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: · patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids. · patients who are symptomatic on current inhaled corticosteroid therapy. · patients who are symptomatic on as needed short-acting beta agonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - fluticasone propionate 0.125mg; salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol - aerosol inhaler, metered dose - 0.125mg/0.025mg per dose - active: fluticasone propionate 0.125mg salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol excipient: ethanol lecithin norflurane - reversible obstructive airways disease (road): indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: · patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids. · patients who are symptomatic on current inhaled corticosteroid therapy. · patients who are symptomatic on as needed short-acting beta agonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - fluticasone propionate 0.25mg; salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol - aerosol inhaler, metered dose - 0.25mg/0.025mg per dose - active: fluticasone propionate 0.25mg salmeterol xinafoate 0.0363mg equivalent to 0.025 mg salmeterol excipient: ethanol lecithin norflurane - reversible obstructive airways disease (road): indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: · patients on effective maintenance doses of long-acting beta-agonists and inhaled corticosteroids. · patients who are symptomatic on current inhaled corticosteroid therapy. · patients who are symptomatic on as needed short-acting beta agonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - fluticasone propionate; salmeterol xinafoate - inhalation powder, pre-dispensed - 50/100 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

imbat limited - fluticasone propionate; salmeterol xinafoate - pressurised inhalation, suspension - 25 microgram/250 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

Ireland - English - HPRA (Health Products Regulatory Authority)

imed healthcare ltd. - fluticasone propionate; salmeterol xinafoate - pressurised inhalation, suspension - 25/125 mcg/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone